Literature DB >> 14986123

Neonatal coxsackie B virus infection-a treatable disease?

Penelope A Bryant1, David Tingay, Peter A Dargaville, Mike Starr, Nigel Curtis.   

Abstract

UNLABELLED: Ten neonates with coxsackie B viral infection presented over a 3-month period. Clinical features included meningoencephalitis, thrombocytopenia, disseminated intravascular coagulopathy, cardiomyopathy, and hepatitis. Eight infants had multiorgan disease, four with severe myocardial dysfunction, of whom two died. All of the infants with severe disease developed symptoms within 7 days of age. In infants presenting within 10 days of birth, in all cases there were symptoms compatible with maternal infection prior to delivery. Severity was associated with perinatal transmission. Enteroviral polymerase chain reaction of CSF, urine, stool or throat swab was positive in nine of the ten babies. Seven of the infants were treated with a 7-day course of the new anti-picornaviral drug pleconaril (5 mg/kg 3 times daily).
CONCLUSION: These cases highlight the importance of not missing coxsackie B viral infection in the differential diagnosis of the septic neonate, especially as there is now a potential treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14986123     DOI: 10.1007/s00431-004-1408-y

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  46 in total

Review 1.  Antiviral therapy for enteroviral infections.

Authors:  H A Rotbart
Journal:  Pediatr Infect Dis J       Date:  1999-07       Impact factor: 2.129

2.  Diagnosis and prospective treatment of enteroviral infections in children.

Authors:  L I Yarush; R W Steele
Journal:  Clin Pediatr (Phila)       Date:  2000-04       Impact factor: 1.168

3.  Enteroviral disease in early infancy.

Authors:  D M Morens
Journal:  J Pediatr       Date:  1978-03       Impact factor: 4.406

4.  Enterovirus infections and enterovirus specific T-cell responses in infancy.

Authors:  S Juhela; H Hyöty; M Lönnrot; M Roivainen; O Simell; J Ilonen
Journal:  J Med Virol       Date:  1998-03       Impact factor: 2.327

5.  Epidemiology of neonatal enterovirus infection.

Authors:  J A Jenista; K R Powell; M A Menegus
Journal:  J Pediatr       Date:  1984-05       Impact factor: 4.406

Review 6.  Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries.

Authors:  J F Modlin
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

7.  Epidemiologic, clinical, and laboratory features of Coxsackie B1-B5 infections in the United States, 1970-79.

Authors:  M Moore; M H Kaplan; J McPhee; D J Bregman; S W Klein
Journal:  Public Health Rep       Date:  1984 Sep-Oct       Impact factor: 2.792

8.  Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin.

Authors:  M J Abzug; H L Keyserling; M L Lee; M J Levin; H A Rotbart
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

9.  Profile of enterovirus disease in the first two weeks of life.

Authors:  M J Abzug; M J Levin; H A Rotbart
Journal:  Pediatr Infect Dis J       Date:  1993-10       Impact factor: 2.129

10.  Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials.

Authors:  Frederick G Hayden; Darrell T Herrington; Teresa L Coats; Kenneth Kim; Ellen C Cooper; Stephen A Villano; Siyu Liu; Spencer Hudson; Daniel C Pevear; Marc Collett; Mark McKinlay
Journal:  Clin Infect Dis       Date:  2003-06-06       Impact factor: 9.079

View more
  9 in total

1.  Coxsackievirus B4 myocarditis and meningoencephalitis in newborn twins.

Authors:  Stephanie J Bissel; Caitlin C Winkler; Joseph DelTondo; Guoji Wang; Karl Williams; Clayton A Wiley
Journal:  Neuropathology       Date:  2014-04-07       Impact factor: 1.906

2.  Hepatitis and Encephalitis due to Coxsackie Virus A9 in an Adult.

Authors:  Brigitte Moreau; Clare Bastedo; Rene P Michel; Peter Ghali
Journal:  Case Rep Gastroenterol       Date:  2011-10-10

3.  Syntheses, Characterizations, and Inhibition Activities Against Coxsackievirus B3 of Iodobenzoic Hydrazide Functionalized Hexamolybdates.

Authors:  Long-Sheng Wang; Chao Guo; Da Hu; Yan-Xi Zhao; Hui-Hui Liu; Yu-Jia Dong; Shang-Bin Sun; Xing Liu; Kang-Hong Hu; Yan-Hong Wei
Journal:  Front Chem       Date:  2022-03-17       Impact factor: 5.221

Review 4.  Platelets and viruses.

Authors:  Silvio Antoniak; Nigel Mackman
Journal:  Platelets       Date:  2021-02-22       Impact factor: 3.862

5.  Antenatal and postnatal diagnosis of coxsackie b4 infection: case series.

Authors:  Jennifer C Hunt; Carol Schneider; Savas Menticoglou; Jayantha Herath; Marc R Del Bigio
Journal:  AJP Rep       Date:  2011-11-25

6.  Reversible Atrioventricular Block and Junctional Ectopic Tachycardia in Coxsackievirus B3-Induced Fetal-Neonatal Myocarditis without Left Ventricular Dysfunction.

Authors:  Hironori Takahashi; Keiko Tsukamoto; Shigehiro Takahashi; Tomoo Nakamura; Yushi Ito; Masahide Kaneko; Haruhiko Sago
Journal:  AJP Rep       Date:  2011-04-11

7.  First report of a Chinese strain of coxsackie B3 virus infection in a newborn in Germany in 2011: a case report.

Authors:  Sebastian Ronellenfitsch; Julia Tabatabai; Sindy Böttcher; Sabine Diedrich; David Frommhold; Susanne Schubert-Bast; Johannes Poeschl; Paul Schnitzler
Journal:  J Med Case Rep       Date:  2014-05-27

8.  Severe Enterovirus Infections in Hospitalized Children in the South of England: Clinical Phenotypes and Causative Genotypes.

Authors:  Hans de Graaf; Emanuela Pelosi; Andrea Cooper; John Pappachan; Kim Sykes; Iain MacIntosh; Diane Gbesemete; Tristan W Clark; Sanjay V Patel; Saul N Faust; Marc Tebruegge
Journal:  Pediatr Infect Dis J       Date:  2016-07       Impact factor: 2.129

9.  Host Cell Calpains Can Cleave Structural Proteins from the Enterovirus Polyprotein.

Authors:  Mira Laajala; Minna M Hankaniemi; Juha A E Määttä; Vesa P Hytönen; Olli H Laitinen; Varpu Marjomäki
Journal:  Viruses       Date:  2019-11-28       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.